{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:40:07Z","timestamp":1793947207852,"version":"4.8.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ijantimicag.2015.01.004","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T13:01:26Z","timestamp":1423314086000},"page":"341-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Appropriate use of fluoroquinolones in children"],"prefix":"10.1016","volume":"45","author":[{"given":"Nicola","family":"Principi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0295","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1368-7646(02)00018-3","article-title":"Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children","volume":"5","author":"Esposito","year":"2002","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0300","first-page":"455","article-title":"Quinolones: a comprehensive review","volume":"65","author":"Oliphant","year":"2002","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0305","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0891-5520(05)70260-9","article-title":"Fluoroquinolones","volume":"14","author":"O\u2019Donnell","year":"2000","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0310","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.mcna.2011.03.006","article-title":"The newer fluoroquinolones","volume":"95","author":"Bolon","year":"2011","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0315","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1542\/peds.2006-1722","article-title":"The use of systemic fluoroquinolones","volume":"118","author":"Committee on Infectious Diseases","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0320","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1542\/peds.2011-1496","article-title":"The use of systemic and topical fluoroquinolones","volume":"128","author":"Bradley","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0325","unstructured":"European Medicines Agency. 5-Year report to the European Commission. General report on the experience acquired as a result of the application of the paediatric regulation. London, UK: EMA. http:\/\/ec.europa.eu\/health\/files\/paediatrics\/2012-09_pediatric_report-annex1-2_en.pdf [accessed 30.01.15]."},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0330","unstructured":"European Medicines Agency. Ciprofloxacin Bayer \u2013 Article 30 referral \u2013 Annex I, II, II [Internet]. London, UK: EMA. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Ciprofloxacin_Bayer\/human_referral_000024.jsp [accessed 30.01.15]."},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2015.01.004_bib0335","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/clinids\/10.Supplement_1.S141","article-title":"Specific toxicologic aspects of the quinolones","volume":"10","author":"Christ","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0340","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/0002-9343(89)90018-1","article-title":"Ciprofloxacin: toxicologic evaluation of additional safety data","volume":"87","author":"Schluter","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0345","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2008.08.004","article-title":"Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data","volume":"33","author":"Sendzik","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0350","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1006\/faat.1995.1146","article-title":"Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin","volume":"28","author":"Linseman","year":"1995","journal-title":"Fundam Appl Toxicol"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0355","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/030098589002700303","article-title":"Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone","volume":"27","author":"Burkardt","year":"1990","journal-title":"Vet Pathol"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0360","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00204-004-0551-6","article-title":"Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period","volume":"78","author":"von Keutz","year":"2004","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0365","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/INF.0b013e3180cc20e4","article-title":"Will fluoroquinolones ever be recommended for common infections in children?","volume":"26","author":"Schaad","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0370","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/AAC.36.5.1086","article-title":"Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children","volume":"36","author":"Peltola","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0375","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/AAC.40.1.29","article-title":"Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients","volume":"40","author":"Schaefer","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0380","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00006454-199701000-00033","article-title":"Pharmacokinetic disposition of sequential intravenous\/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation","volume":"16","author":"Rubio","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0385","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0091270004271944","article-title":"Levofloxacin pharmacokinetics in children","volume":"45","author":"Chien","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0390","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciu868","article-title":"Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis","volume":"60","author":"Thee","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0395","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/01.inf.0000246828.13834.f9","article-title":"An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media","volume":"25","author":"Arguedas","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0400","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/INF.0b013e318168d2cb","article-title":"A randomized comparative study of levofloxacin versus amoxicillin\/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media","volume":"27","author":"Noel","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0405","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/INF.0b013e3180cbd2c7","article-title":"Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia","volume":"26","author":"Bradley","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0410","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ppul.22755","article-title":"Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience","volume":"49","author":"Garazzino","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0415","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/j.1442-200X.2012.03735.x","article-title":"Peritoneal tuberculosis due to multidrug-resistant Mycobacterium tuberculosis","volume":"55","author":"Esposito","year":"2013","journal-title":"Pediatr Int"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0420","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ppul.22667","article-title":"Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. Fluoroquinolones","volume":"48","author":"Stockmann","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0425","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00006454-199706000-00007","article-title":"Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group","volume":"16","author":"Richard","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0430","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199701000-00031","article-title":"Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime\/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group","volume":"16","author":"Church","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0435","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00006454-199701000-00032","article-title":"Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis","volume":"16","author":"Schaad","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0440","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1592\/phco.30.12.1252","article-title":"Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis","volume":"30","author":"Guillot","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0445","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF01967005","article-title":"Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal","volume":"10","author":"LeBel","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0450","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1753465813508445","article-title":"Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"8","author":"Stockmann","year":"2014","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0455","first-page":"937","article-title":"Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations","volume":"33","author":"Luo","year":"1998","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0460","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1128\/AAC.47.10.3104-3108.2003","article-title":"Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy","volume":"47","author":"Pea","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0465","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11908-003-0011-0","article-title":"Fluoroquinolones in the treatment of meningitis","volume":"5","author":"Cottagnoud","year":"2003","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0470","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0475","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0163-4453(93)95291-P","article-title":"The treatment of neonatal meningitis due to Gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid","volume":"26","author":"Green","year":"1993","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0480","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jac\/26.5.727","article-title":"Neonatal meningitis due to Salmonella typhimurium treated with ciprofloxacin","volume":"26","author":"Ragunathan","year":"1990","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"10.1016\/j.ijantimicag.2015.01.004_bib0485","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jac\/26.suppl_B.187","article-title":"Pefloxacin efficacy in Gram-negative bacillary meningitis","volume":"26","author":"Segev","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0490","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1651-2227.1996.tb14106.x","article-title":"Neonatal Salmonella meningitis: two case reports","volume":"85","author":"Hansen","year":"1996","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0495","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0022-3476(05)81210-7","article-title":"Use of ciprofloxacin in an infant with ventriculitis","volume":"121","author":"Geopp","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0500","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijantimicag.2011.01.008","article-title":"Levofloxacin for the treatment of Mycoplasma pneumoniae-associated meningoencephalitis in childhood","volume":"37","author":"Esposito","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0505","first-page":"CD004785","article-title":"Antibiotics for preventing meningococcal infections","volume":"10","author":"Zalmanovici Trestioreanu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0510","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/171.3.728","article-title":"Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin","volume":"171","author":"Cuevas","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0515","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1345\/aph.18146","article-title":"Clinical use of fluoroquinolones in children","volume":"34","author":"Alghasham","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0520","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/INF.0b013e318245ab48","article-title":"Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials","volume":"31","author":"Sung","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0525","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00520-011-1333-3","article-title":"A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia","volume":"20","author":"Manji","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0530","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/INF.0b013e318242590e","article-title":"A meta-analysis of antipseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia","volume":"31","author":"Manji","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0535","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11534380-000000000-00000","article-title":"Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials","volume":"12","author":"Comstock","year":"2010","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0540","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14740338.2013.796362","article-title":"Risks associated with the therapeutic use of fluoroquinolones","volume":"12","author":"Stahlmann","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0545","unstructured":"Ciprofloxacin package insert. http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=457d7810-23f1-4318-9561-2cd58a9cf973 [accessed 24.11.14]."},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0550","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/00365540701849931","article-title":"Severe acute polyarthritis in a child after high doses of moxifloxacin","volume":"40","author":"Torres","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0555","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/INF.0b013e3180cbd382","article-title":"Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders","volume":"26","author":"Noel","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0560","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1542\/peds.2013-3636","article-title":"Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin","volume":"134","author":"Bradley","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0565","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-011-0132-6","article-title":"Extended-spectrum \u03b2-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy","volume":"39","author":"Meier","year":"2011","journal-title":"Infection"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2015.01.004_bib0570","first-page":"ii41","article-title":"Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001\u201306","volume":"62","author":"Livermore","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0575","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.05.021","article-title":"TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents","volume":"30","author":"Morrissey","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.01.004_bib0580","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1097\/INF.0000000000000238","article-title":"The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children","volume":"33","author":"Rose","year":"2014","journal-title":"Pediatr Infect Dis J"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T14:53:28Z","timestamp":1566312808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0924857915000527"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.01.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appropriate use of fluoroquinolones in children","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}